Novartis
Novartis Enhances Mid-Term Growth Projections Following Strategic Transformation
Novartis, mid-term guidance, growth projections, pharmaceutical industry, innovative medicines, pipeline development
Novartis CEO Reveals Strategic Pipeline Reduction by 40% Based on Data-Driven Insights
Novartis, clinical pipeline, data-driven decisions, pharmaceutical industry, strategic reduction
Novartis and Ratio Therapeutics Ink $745M Radiopharmaceutical Deal
Novartis, Ratio Therapeutics, radiopharmaceutical pact, $745M deal, cancer treatment
Novartis and Schrödinger Forge $150M Drug Discovery Partnership with Billions in Potential Milestones
Novartis, Schrödinger, drug discovery pact, $150M upfront payment, multiyear collaboration, multi-target agreement.
Novartis Joins Eurovision 2025 as Official Partner
Eurovision 2025, Novartis, Official Partner, Basel, Switzerland
Novartis Secures First-Line Approval for Scemblix in Newly Diagnosed Chronic Myeloid Leukemia Patients
Scemblix, Novartis, first-line approval, chronic myeloid leukemia, CML, newly diagnosed, FDA approval
Novartis Secures FDA Approval for Scemblix as First-Line Treatment for Newly Diagnosed CML, Anticipates $3B in Peak Sales
Novartis, Scemblix, FDA Approval, First-Line Treatment, CML, Chronic Myeloid Leukemia, ASC4FIRST Trial, Tyrosine Kinase Inhibitors, STAMP Inhibitor
Novartis’ $2.9B MorphoSys Acquisition Hits Roadblock as Safety Concerns Delay Approval Filing
Novartis, MorphoSys, safety signal, delayed approval, biotech, pharmaceuticals
Novartis and Monte Rosa Collaborate on $2.2B Molecular Glue Degrader Alliance
Novartis, Monte Rosa, molecular glue degraders, biopharma collaboration, protein degradation, oncology, neurological diseases
Novartis Invests $150M in Monte Rosa’s Molecular Glue Technology for Autoimmune Diseases
Novartis, Monte Rosa, Molecular Glue, Protein Degradation, Autoimmune Diseases, MRT-6160, VAV1-degrader, Biotech Collaboration